The U.S. Food and Drug Administration is urging consumers to immediately stop using a specific herbal supplement after laboratory analysis confirmed it contains sildenafil, the active pharmaceutical ingredient in the prescription drug Viagra. The agency issued a public safety notification on March 15, 2026.
Undeclared Drug Poses Serious Health Risks
The FDA stated the presence of sildenafil was not listed on the product label. This undisclosed ingredient poses significant health risks, particularly for individuals with certain pre-existing conditions. Sildenafil can interact dangerously with prescription medications containing nitrates, commonly used for heart conditions.
Such interactions can cause a severe drop in blood pressure. The agency warned that consumers may be unaware of the potential for serious adverse events. “Products that contain hidden drugs pose a direct threat to consumer health,” the FDA notification said.
Specific Product Identified
While the FDA’s public announcement did not name the specific brand in its initial summary, the agency’s full laboratory report is expected to provide detailed product information, including lot numbers and distribution channels. The product was marketed as a natural herbal supplement for male sexual enhancement.
Regulatory officials note this is a recurring issue in the dietary supplement market. The FDA has issued numerous warnings over the years about so-called “all-natural” products spiked with prescription drugs. Consumers often purchase these items online or in retail stores without a prescription, believing them to be safe herbal alternatives.
Broader Regulatory Context
This incident highlights ongoing challenges in the dietary supplement industry. Unlike prescription drugs, supplements do not require pre-market approval from the FDA for safety and efficacy. The agency primarily acts after products are on the market, relying on adverse event reports and its own testing.
The FDA’s enforcement actions typically begin with public warnings and can escalate to product seizures, injunctions, or criminal prosecution. The agency maintains a public database of tainted sexual enhancement products where consumers can check for previous alerts.
Consumer Advice and Next Steps
The FDA advises consumers who have used the product to discontinue use immediately and consult a healthcare professional. Individuals should discuss any sexual health concerns with a doctor to obtain safe and appropriate treatment options.
Healthcare providers are encouraged to report any adverse events related to this or similar products to the FDA’s MedWatch program. The agency uses these reports to identify patterns and take further regulatory action. Consumers can also report problems directly through the FDA Safety Reporting Portal.
Retailers and distributors have been instructed to remove the product from shelves. The FDA’s investigation is ongoing to determine the full scope of distribution. Further regulatory steps will depend on the cooperation of the responsible company and the severity of the public health risk.
This article was produced with AI assistance and reviewed by our editorial team for accuracy and quality.
